8:45 am Coffee & Networking

9:20 am Chair’s Opening Remarks

• Nina Horowitz Chief Scientific Officer, ImmuneBridge

Enhancing Therapeutic Precision to Identify Critical Biomarkers, Establish Rigorous Specificity Standards, & Improve the Accuracy & Effectiveness Of Cell Therapy Interventions

9:30 am Fireside Chat: Mapping the Crucial Role of Donor Selection in the Future of Biotech & Pharma to Streamline Commercialization

• Ben Beneski Vice President - Product Development & Manufacturing, Allogene Therapeutics
• Armin Rath Head of New Product Development, Cytovia Therapeutics
• Stephanie Dormesy Senior Director - Cell Sourcing Partnerships Clinical Services Administration, Comprehensive Cell Solutions
• Nina Horowitz Chief Scientific Officer, ImmuneBridge

10:15 am Comparing Donor-Derived & iPSC-Derived Therapies for Market Entry & Long-Term Viability

• Armin Rath Head of New Product Development, Cytovia Therapeutics

10:45 am Morning Refreshments & Networking

11:45 am Enhancing Donor Selection in Autologous Cell Therapy: Overcoming Challenges in Process Optimization & Scaling Up with Consistency & Safety

• Nidheesh Dadheech Cell Therapy Lead, University of Alberta

Integrating Robust Donor Selection Methods into Manufacturing, Scale-Up Operations & Downstream Drug Development to Maximize Therapeutic Effects

12:15 pm Pre-Clinical Ex Vivo Efficacy for Cell & Gene Therapies – A Donor Case Study

• Raluca Dumitru Director - Scientific Sales, Charles River Laboratories

Critical Considerations in Donor Selection: Balancing Safety, Risk-Benefit Profiles, & Selecting Optimal Starting Materials between Donor-Derived & iPSC Therapies

12:30 pm Audience Led Discussion: Balancing Safety & Benefit-Risk in Donor Selection by Evaluating Metabolic Fitness, Memory & Cytokine Risks

• Nina Horowitz Chief Scientific Officer, ImmuneBridge

1:00 pm Lunch & Networking

2:00 pm Advancing Cryopreservation Strategies for Donor Products by Enhancing Viability, Ensuring Long-Term Stability, & Maximizing Therapeutic Efficacy

• Tracey Turner Principal Scientist - Formulation & Cryobiology, Bristol Myers Squibb

2:30 pm Roundtable Discussion: Evaluating Starting Materials for Donor Cells with a Focus on Quality, Reliability, & Logistics Considerations

• Stephen Chen Chief Technical Officer, Tevogen Bio

3:00 pm Chair’s Closing Remarks

• Jesse Cotari Co-Founder & Scientific Advisor, ImmuneBridge

3:15 pm Close of Summit